The ADAURA trial has been significant for the perception of EGFR tyrosine kinase inhibitors (TKIs) as a tool for early stage non-small-cell lung cancer (NSCLC). It produced such great insight that the main TKI, Osimertinib, was rapidly integrated into international guidelines for adjuvant use. However, EGFR-mutant NSCLC is a complex entity and has various targeting drugs, and the benefits for patients might not be as clear as they seem. We reviewed trials and meta-analyses considering TKI adjuvant and neoadjuvant use. We also explored the influence of mutation variability and financial evaluations. We found that TKIs often show disease-free survival (DFS) benefits, yet studies have struggled to improve the overall survival (OS); however, the results from the literature might be confusing because of variability in the stages and mutations. The safety profiles and adverse events are acceptable, but costs remain high and accessibility might not be optimal. TKIs are promising drugs that could allow for tailored treatment designs.
Introduction: The outcome of the primary lung neuroendocrine tumors surgery at metastatic stage remains poorly characterized. Methods: We conducted a retrospective national study including patients with metastatic lung neuroendocrine tumors at diagnosis. We performed a safety study to evaluate major morbidity and mortality of surgical resection of the primary tumor, and compared data in operative and non-operative group. Results: A total of 155 patients were included, 41 in the operative group and 114 in the non-operative group. The median age was 64 years. Metastases were mainly located in the liver (74.2%) and the bone (49.7%). The primary end-point was met as the rate of major complications was 4.9% and there was no post-operative mortality. In the operative group 42.5% of patients had improvement of their pulmonary symptoms, versus only 14.4% in the non-operative group. The median overall survival was not reached in the operative group and 4.3 years (95%CI [3.5;4.9]) in the non-operative group (univariate analysis, HR=0.42 95%CI [0.23;0.77], p=0.002). After multivariate analysis, only an ECOG-PS ≥1 (versus 0, HR=2.44, 95%CI [1.46;4.07], p=0.001) and >1 metastatic site (versus 1; HR=1.83, 95%CI [1.06;3.16], p=0.030) remained significantly associated with overall survival. The resection of the primary tumor was not significantly associated with OS (HR=0.63, 95%CI [0.32;1.24], p=0.183). Conclusions: Surgery of the primary lung neuroendocrine tumors at metastatic stage is a safe option that should be considered in selected patients in order to improve symptoms, with a view to improve their quality of life. Larger studies are warranted to evaluate the impact of surgery on survival.
Introduction: Segmentectomy for non-small cell lung cancer (NSCLC) is increasingly performed for small-sized lesions. However, prognostic factors associated with poor outcomes after this lung-sparing oncologic surgery remain uncertain. Methods: We conducted a single-center retrospective study including 100 consecutive patients who underwent single or multiple segmentectomies for NSCLC in real-world practice. Results: In univariate analyses, compromise segmentectomy (HR 3.52; p = 0.005), complex segmentectomy (HR 2.56; p = 0.020), SUVmax ≥ 6 (HR 2.86; p = 0.017), and thoracotomy (HR 2.62; p = 0.020) were associated with worse overall survival. In multivariable analysis, compromise segmentectomy remained associated with worse overall survival (HR 3.47; p = 0.026). Regarding recurrence, thoracotomy was associated with poorer disease-free survival (HR 2.77; p = 0.040). Conclusion: In this real-world cohort, compromise segmentectomy identified a high-risk subgroup with impaired overall survival, probably reflecting baseline frailty and comorbidity rather than a clearly demonstrated increase in recurrence. These findings support careful preoperative selection and counseling of patients considered for lung-sparing resection outside standard indications.